Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

Published on 17 Feb 2025
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended glofitamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The decision was based on uncertain clinical effectiveness and unfavourable cost effectiveness of glofitamab compared with relevant comparators, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for glofitamab are provided in the Annex.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy (17 Feb 2025) [PDF, 217 KB]

PES Glofitamab for previously treated relapsed or refractory diffuse large B-cell lymphoma (17 Feb 2025) [PDF, 97 KB]